Guardant Health, Inc. (GH)’s ctDNA Test Predicts Colon Cancer Recurrence Risk in Stage III Patients

Guardant Health, Inc. (NASDAQ:GH) and research collaborators have unveiled results from the largest study to date on circulating tumor DNA (ctDNA) testing in stage III colon cancer, presented at the 2025 ASCO Annual Meeting. Analyzing over 2,000 patients from the NCCTG N0147 phase III trial, researchers demonstrated that the Guardant Health, Inc. (NASDAQ:GH) Reveal blood test, performed after surgery and before adjuvant chemotherapy, is a powerful predictor of cancer recurrence and survival outcomes.

Analysing a blood sample, a technician in a lab coat using precision diagnostic equipment.

Key findings showed that 62.6% of patients with detectable ctDNA post-surgery experienced cancer recurrence within three years, compared to just 15.4% of those without detectable ctDNA, despite both groups receiving chemotherapy. The test’s ability to measure tumor fraction also offered insights into which patients are less likely to clear residual disease with standard treatment.

Experts say these results support the routine use of ctDNA testing to better stratify risk and personalize post-operative management in stage III colon cancer patients. Study lead, Dr. Frank Sinicrope of Mayo Clinic, made the following comment:

“Analysis of postsurgical ctDNA can improve the prediction of disease recurrence over standard staging criteria, which may help guide patient management and follow-up.”

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.